Avalo Therapeutics, Inc. (AVTX) at Guggenheim 3rd Annual Healthcare Innovation Conference - AVALO THERAPEUTICS INC

Explicit Guidance:

• Capital Runway: $462 million in cash at end of September 2023 sufficient to fund Phase 3 trials and second indication development through 2029 without additional capital raises.
• Phase 3 Timing: Preparation to "hit the ground running" in early 2027 pending FDA/EMA feedback expected before year-end 2023.
• AVTX-010 Milestones: Engineering and CMC activities ongoing; IND filing and clinic initiation scheduled for 2027.
• Clinical Endpoints: Proposed Phase 3 primary endpoint is PASI 75 (High Score 75), with step-down analysis to PASI 50 and inclusion of IHS4-75 for secondary evaluation.

Business-Segment Outlook:

• Primary Indication (HS): Aiming to establish a premium offering in the IL-1 beta category, anticipating market share growth as IL-17 dominance (e.g., UCB) faces competition from emerging mechanisms and combination therapies.
• Secondary Indication: A new therapeutic area under evaluation, leveraging IL-1 beta/NLRP3 biology; management expects this market to be less crowded than HS with a credible pathway to FDA approval and labeling.
• Pipeline Expansion: Strategic focus on combination therapies (e.g., with IL-17s or other biologics) to drive patients toward remission, viewing IL-1 beta drugs as ideal low-risk components for such regimens.
• Product Differentiation: AVTX-010 engineered for extended half-life and high affinity; projected to outperform legacy agents (e.g., Litikizumab) due to pure IL-1 beta targeting (avoiding IL-1 alpha "baggage") and superior binding kinetics.

Market and Competitive Outlook:

• Market Maturation: Anticipates the HS market evolving similarly to IBD, shifting from monotherapy to multi-mechanism combination approaches to achieve high rates of clearance and remission.
• Competitive Landscape: Current market dominated by IL-17s (UCB, AbbVie); expects TNF decline due to inferior durability. Predicts a fragmented landscape where no single mechanism dominates, driven by patient demand for choice.
• Treatment Paradigm Shift: Forecasting a rapid reduction in the "diagnostic and referral lag" (currently 8–12 years) as patient awareness and physician adoption of biologics accelerate.
• Market Penetration: Significant growth opportunity exists as current biologic penetration remains low (approx. 10,000 patients on drug per recent industry data).

Macro / Industry Outlook:

• Clinical Trial Environment: Acknowledges a "new norm" of elevated placebo rates (approx. 25% on PASI 75) in dermatology trials; committing to higher study power and stricter patient stratification in Phase 3 to mitigate this headwind.
• Regulatory Trajectory: Aligning with FDA/ICH guidelines requiring a total safety database of ~1,500 patients and at least 100 patients followed for one year.

Strategic Initiatives:

• Phase 3 Study Design: Proposing a dual-trial program (rather than single) to de-risk approval; includes leveraging the completed LOTUS Phase 2 data as a potential "pivotal" backup if the second trial encounters issues (referencing Moon Lake precedent).
• Scale-Up: Upsizing company resources and lining up CROs/CMOs to execute parallel programs efficiently.
• Indication Expansion: Pursuing new indications only after confirming clinical proof of concept and measurable outcomes suitable for labeling.

Risks and Headwinds to Outlook:

• Placebo Rate Variability: High placebo response rates in clinical trials could obscure drug efficacy signals, requiring larger sample sizes.
• Regulatory Uncertainty: Dependence on FDA/EMA feedback regarding the proposed Phase 3 design and endpoint selection (PASI 75 vs. PASI 50).
• Bispecific Mechanism Risks: Highlighting specific risks associated with targeting IL-1 alpha (potential exacerbation of skin infection due to loss of "alarmant" function; high affinity sink in normal tissue reducing drug availability to lesions).
• Trial Execution Risk: While two trials mitigate the risk of a single failure, managing the logistics and cost of a dual-study program remains a focus.

Management Tone on the Future:

• Confidence Level: High confidence in the LOTUS data consistency (dose-response, deep response, safety) and the mechanistic rationale for IL-1 beta over IL-1 alpha.
• Strategic Hedges: "Very carefully" managing capital with the aim of avoiding dilution; "baking into" Phase 3 design the learnings from Phase 2 regarding placebo and patient stratification.
• Growth Outlook: Expresses excitement and "great confidence" regarding the potential for the drug to capture a premium market share in a maturing, expanding HS ecosystem.

Miscellaneous:

• Data Consistency: LOTUS trial demonstrated consistent efficacy across doses (600mg/300mg q4w vs. 300mg/150mg q2w) and patient subgroups (naive vs. biologic-experienced), supporting a simplified dosing strategy.
• Safety Profile: Observed "very benign" safety profile with no significant difference from placebo regarding SAEs, neutropenia, or infections.